## **ONCOLYTIC VIRUS THERAPY** GLOBAL CLINICAL TRIAL LANDSCAPE (2024)

**#DYK** Did you know?



**Dual Mechanism of Action:** Direct tumor cell destruction and immune system activation



**Advanced Delivery Systems:** Nanoparticle carriers improve targeting and stability

Oncolytic viruses are engineered to selectively

destroy cancer

cells

while

sparing normal

cells

Genetic Engineering: Tailoring oncolytic virus therapy with tumor-specific promoters and immune enhancers


**Applications:** Effective against solid tumors, melanoma, pancreatic, and alioblastoma cancers

Broadening applications to autoimmune diseases, neurological disorders, and infectious diseases

US dominates funding with \$405.2M, driving early-phase research and development

China and Canada follow as key contributors to advancing global oncolytic virus therapy innovation

## **TRIAL DISTRIBUTION:**



## TARGETED **THERAPEUTIC AREAS:**

ONCOLOGY

5% INFECTIOUS DISEASES & GENETIC DISORDERS



2019 - 2024 **Oncolytic virus** therapy trials: (CAGR: 14.2%)

**Fastest CAGR** Asia-Pacific: (14.9%)

30%

Trial Leaders: US. Mainland China

**Phase I** (~50%)

Combination therapies are gaining the focus of innovators

The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: communications@novotech-cro.com